Q3 2017 Earnings Forecast for Allergan PLC. (AGN) Issued By Gabelli
Allergan PLC. (NYSE:AGN) – Investment analysts at Gabelli raised their Q3 2017 earnings per share (EPS) estimates for shares of Allergan PLC. in a report issued on Monday. Gabelli analyst K. Kedra now expects that the company will post earnings of $4.16 per share for the quarter, up from their prior forecast of $4.09. Gabelli also issued estimates for Allergan PLC.’s Q4 2017 earnings at $4.72 EPS.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period last year, the firm posted $3.35 earnings per share. The business’s revenue was up 8.8% on a year-over-year basis.
Several other analysts have also commented on AGN. Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Monday, June 12th. Mizuho lowered their target price on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. UBS AG reiterated a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a report on Monday, May 15th. Finally, Citigroup Inc. lifted their target price on shares of Allergan PLC. to $261.00 and gave the company a “buy” rating in a report on Monday, April 24th. Eight analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $275.49.
Shares of Allergan PLC. (NYSE AGN) opened at 231.14 on Wednesday. The firm has a market capitalization of $77.27 billion, a PE ratio of 7.04 and a beta of 1.16. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The stock has a 50 day moving average price of $245.03 and a 200-day moving average price of $238.77.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.21%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is currently 9.95%.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in the company. Israel Discount Bank of New York acquired a new stake in shares of Allergan PLC. during the first quarter valued at about $988,000. Trust Co. of Vermont boosted its stake in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after buying an additional 1,109 shares in the last quarter. Capital Planning Advisors LLC boosted its stake in shares of Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock valued at $878,000 after buying an additional 1,625 shares in the last quarter. First Long Island Investors LLC acquired a new stake in shares of Allergan PLC. during the first quarter valued at about $4,826,000. Finally, Rehmann Capital Advisory Group boosted its stake in shares of Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock valued at $425,000 after buying an additional 237 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.